Results 21 to 30 of about 11,087,757 (202)
Clinical Case Reports, 2020 We experienced two cases of dipeptidyl peptidase‐4 (DPP‐4) inhibitor‐associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation.
Yasutake Shinohara +8 more
doaj +1 more source
Characterization of Schnurri : an integral component of the Dpp-signaling pathway in "Drosophila melanogaster" [PDF]
, 2004 Signaling by the transforming growth factor-β (TGF-β) family of ligands plays a crucial role during development and tissue homeostasis in all multicellular organisms. The signal transduction pathway is highly conserved and relatively simple.
Hartmann, Britta
core +1 more source
DPP-4 mediating insulin resistance and lipogenesis.
, 2022 HepG2 cells were incubated with OAPA and 50 μM of linagliptin for 24 h, and then analyzed the cytotoxicity (A), DPP-4 activity (B), the expression of FAS (C) and insulin resistance (D) signals. For the cytotoxicity and DPP-4 activity, data were presented
Yaw-Bee Ker (515378) +5 more
core +1 more source
The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure
Journal of Pharmacological Sciences, 2017 Dipeptidyl peptidase-4 (DPP-4) inhibitors are hypoglycemic agents. DPP-4 inhibitor has cardioprotective effects after transverse aortic constriction (TAC), but role of DPP-4 on cardiac fibrosis after TAC is not well known.
Masanori Hirose +6 more
doaj +1 more source
Frontiers in Endocrinology, 2021 AimAt present, daily DPP-4 inhibitors are quite frequently prescribed in subjects with type 2 diabetes mellitus (T2DM). Recently, it has been drawing much attention that once-weekly incretin-based injection dulaglutide was developed.
Junpei Sanada +14 more
doaj +1 more source
Regulation of Dpp target genes by Mad/Medea and Brinker [PDF]
, 2009 The TGF-β family member Decapentaplegic (Dpp) is a key regulator of patterning and growth in development of Drosophila. Binding of Dpp to its receptors triggers the activation of the intracellular Smad pathway.
Weiss, Alexander
core +1 more source
Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin [PDF]
Diabetes & Metabolism Journal, 2015 BackgroundDipeptidyl peptidase-4 (DPP-4) inhibitor add-on therapy is a new option for patients with inadequately controlled type 2 diabetes who are taking combined metformin and sulfonylurea (SU).
Ye An Kim +9 more
doaj +1 more source
DPP-4 Inhibitors—Renoprotection in Diabetic Nephropathy? [PDF]
Diabetes, 2014 There is no doubt that rates of chronic kidney disease are escalating and that this rise is the main contributor to the increasing prevalence of diabetic nephropathy. It is also clear that the increase in kidney failure continues despite tight blood glucose and blood pressure control, as well as renin-angiotensin system blockade.
Usha, Panchapakesan, Carol A, Pollock
openaire +2 more sources
Efficacy and Safety of Dpp-4 Inhibitor Use in the Hospital Setting [PDF]
, 2023 Current practice in the hospital is to hold oral antidiabetic drugs and administer insulin to prevent adverse reactions. This can lead to issues including hypoglycemic events, high glycemic variability, and poorly controlled blood glucose. Newer incretin
Dass, Brendan
core +1 more source
Cardiovascular effects of the DPP-4 inhibitors
Diabetes and Vascular Disease Research, 2012 Type 2 Diabetes continues to rise in prevalence throughout the globe, and cardiovascular diseases remain the most common cause of morbidity and mortality among patients. Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents whose effect is mediated through the incretin hormones, GLP-1 and GIP.
Tessey, Jose, Silvio E, Inzucchi
openaire +2 more sources